Following on from the promising results that have emerged to date from bevacizumab (Avastin) for the treatment of tumor growth and resulting hearing loss in NF2, a new Avastin NF2 trial will open shortly. The trial aims to improve hearing and decrease the size of vestibular tumors and is being opened on October 18, 2010. This study is a collaboration between Johns Hopkins Hospital (serving as the primary coordinating site), Massachusetts General Hospital and the National Cancer Institute. People with NF2 who are 12 years of age or older and who have recently experiences hearing loss due to their vestibular tumors may be eligible for this study. People with NF2 who have worsening hearing in their only hearing ear are considered particularly appropriate study candidates. If you are interested in participating in this study or learning more about it, please contact Amanda Bergner in the Central Study Office at Johns Hopkins at 410-502-6732 or abergne1@jhmi.edu.
New NF2 Avastin Trial to Open at Johns Hopkins, MGH and NIH
